Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout
(NASDAQ: TRVI) Delayed: 18.46 +0.31 (1.71%)
Previous Close $18.15    52 Week High $ 
Open $17.98    52 Week Low $ 
Day High $18.54    P/E N/A 
Day Low $17.63    EPS $ 
Volume 1,389,772